Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable
- PMID: 16617275
- PMCID: PMC2715942
- DOI: 10.1097/01.ede.0000193606.58671.c5
Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable
Abstract
Background: Postmarketing observational studies of the safety and effectiveness of prescription medications are critically important but fraught with methodological problems. The data sources available for such research often lack information on indications and other important confounders for the drug exposure under study. Instrumental variable methods have been proposed as a potential approach to control confounding by indication in nonexperimental studies of treatment effects; however, good instruments are hard to find.
Methods: We propose an instrument for use in pharmacoepidemiology that is based on a time-varying estimate of the prescribing physician's preference for one drug relative to a competing therapy. The use of this instrument is illustrated in a study comparing the effect of exposure to COX-2 inhibitors with nonselective, nonsteroidal antiinflammatory medications on gastrointestinal complications.
Results: Using conventional multivariable regression adjusting for 17 potential confounders, we found no protective effect due to COX-2 use within 120 days from the initial exposure (risk difference = -0.06 per 100 patients; 95% confidence interval = -0.26 to 0.14). However, the proposed instrumental variable method attributed a protective effect to COX-2 exposure (-1.31 per 100 patients; -2.42 to -0.20) compatible with randomized trial results (-0.65 per 100 patients; -1.08 to -0.22).
Conclusions: The instrumental variable method that we have proposed appears to have substantially reduced the bias due to unobserved confounding. However, more work needs to be done to understand the sensitivity of this approach to possible violations of the instrumental variable assumptions.
Figures
Similar articles
-
The proportion of all previous patients was a potential instrument for patients' actual prescriptions of nonsteroidal anti-inflammatory drugs.J Clin Epidemiol. 2016 Jan;69:96-106. doi: 10.1016/j.jclinepi.2015.08.008. Epub 2015 Sep 2. J Clin Epidemiol. 2016. PMID: 26341022
-
Instantaneous preference was a stronger instrumental variable than 3- and 6-month prescribing preference for NSAIDs.J Clin Epidemiol. 2008 Dec;61(12):1285-1288. doi: 10.1016/j.jclinepi.2008.01.003. Epub 2008 May 20. J Clin Epidemiol. 2008. PMID: 18495427 Free PMC article.
-
COX-2 selective nonsteroidal anti-inflammatory drugs and risk of gastrointestinal tract complications and myocardial infarction: an instrumental variable analysis.Epidemiology. 2013 May;24(3):352-62. doi: 10.1097/EDE.0b013e318289e024. Epidemiology. 2013. PMID: 23532054 Clinical Trial.
-
A theoretical exploration of therapeutic monomania as a physician-based instrumental variable.Pharmacoepidemiol Drug Saf. 2020 Jan;29 Suppl 1(Suppl 1):45-52. doi: 10.1002/pds.4757. Epub 2019 May 15. Pharmacoepidemiol Drug Saf. 2020. PMID: 31094048 Free PMC article. Review.
-
Comparative effectiveness research considered methodological insights from simulation studies in physician's prescribing preference.J Clin Epidemiol. 2022 Aug;148:74-80. doi: 10.1016/j.jclinepi.2022.04.020. Epub 2022 Apr 18. J Clin Epidemiol. 2022. PMID: 35447357 Review.
Cited by
-
Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.JAMA. 2018 Aug 7;320(5):469-477. doi: 10.1001/jama.2018.9824. JAMA. 2018. PMID: 30088010 Free PMC article.
-
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study.Am J Epidemiol. 2010 Oct 1;172(7):843-54. doi: 10.1093/aje/kwq198. Epub 2010 Aug 17. Am J Epidemiol. 2010. PMID: 20716704 Free PMC article.
-
Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study.Int J Clin Oncol. 2019 Nov;24(11):1449-1458. doi: 10.1007/s10147-019-01506-x. Epub 2019 Jul 12. Int J Clin Oncol. 2019. PMID: 31300904
-
Collaborative-controlled LASSO for constructing propensity score-based estimators in high-dimensional data.Stat Methods Med Res. 2019 Apr;28(4):1044-1063. doi: 10.1177/0962280217744588. Epub 2017 Dec 11. Stat Methods Med Res. 2019. PMID: 29226777 Free PMC article.
-
Comparison of hospital treatment strategy or of treatment actually received in COVID-19?: Commenting on: Lammers AJJ, Brohet RM, Theunissen REP, Koster C, Rood R, Verhagen DWM, et al. Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. Int J Infect Dis. 2020 September.Int J Infect Dis. 2021 Feb;103:516. doi: 10.1016/j.ijid.2020.12.007. Epub 2020 Dec 9. Int J Infect Dis. 2021. PMID: 33310025 Free PMC article. No abstract available.
References
-
- Avorn J. Powerful medicines: the benefits, risks, and costs of prescription drugs. New York: Knopf; 2004.
-
- Jick H. The discovery of drug-induced illness. N Engl J Med. 1977;296:481–5. - PubMed
-
- The Centers for Education and Research on Therapeutics (CERTs) Risk Assessment Workshop Participants: Risk assessment of drugs, biologics and therapeutic devices: present and future issues. Pharmacoepidemiol Drug Saf. 2003;12:653–662. - PubMed
-
- Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005 in press. - PubMed
-
- Walker AM. Confounding by indication. Epidemiology. 1996;7:335–336. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials